All In Biotech

NDA 210821 · Bausch Lomb Ireland

Tetracaine Hydrochloride

Tetracaine Hydrochloride · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 12, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

110

23 Phase 3, 1 recruiting

FAERS reports

133

118 serious, 17 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 7, 2026.

Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )

Mechanism: Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • TETRACAINE HYDROCHLORIDE · TETRACAINE HYDROCHLORIDE 0.5% · SOLUTION, OPHTHALMIC · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Tetracaine" as an intervention, any sponsor and status, largest first.

All 110 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxic anterior segment syndrome31
  • nausea15
  • syncope15
  • aqueous fibrin14
  • inflammation14
  • abdominal discomfort12
  • pain12
  • sudden death12
  • muscle spasms11
  • oropharyngeal pain11
  • hypersensitivity9
  • hypotension9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20061
20082
20094
20103
20111
201211
20131
20141
20151
20162
20173
201815
20196
20204
20218
202227
20236
20247
202512
202617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 337 on PubMed

Sponsor: Bausch Lomb Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.